Patents by Inventor Binxia YANG

Binxia YANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORY NUCLEIC ACIDS FOR ITFG1
    Publication number: 20260167969
    Abstract: Provided herein are nucleic acids for decreasing the expression of ITFG1, and methods for using the same, including methods of medical treatment and prophylaxis.
    Type: Application
    Filed: June 28, 2023
    Publication date: June 18, 2026
    Applicant: LERNA BIOPHARMA PTE. LTD.
    Inventors: Yann Chong TAN, Si Hui TAN, Binxia YANG, Xi LIN, Mei Jia TAN, Audrey Shimei WANG
  • METHODS AND MATERIALS FOR ASSESSING AND TREATING NEUROLOGIC AUTOIMMUNE DISORDERS AND/OR CANCER
    Publication number: 20260160763
    Abstract: This document relates to methods and materials involved in assessing and/or treating mammals having a neurological autoimmune disorder (e.g., a paraneoplastic neurological autoimmune disorder) and/or cancer. For example, methods and materials for detecting anti-neuronal nuclear antibody type 3 (ANNA3) antibodies are provided.
    Type: Application
    Filed: November 15, 2022
    Publication date: June 11, 2026
    Inventors: Anastasia Zekeridou, Vanda A. Lennon, Sean J. Pittock, Binxia Yang, Eoin P. Flanagan
  • A METHOD OF DIFFERENTIATING AN INDUCED PLURIPOTENT STEM CELL INTO A RETINAL PIGMENT EPITHELIAL CELL, A RETINAL PIGMENT EPITHELIAL CELL AND METHODS OF USING THE RETINAL PIGMENT EPITHELIAL CELL
    Publication number: 20250197803
    Abstract: The present invention relates to a method of differentiating an induced pluripotent stem cell into a retinal pigment epithelial cell. Additionally, the present invention relates to a retinal pigment epithelial cell culture obtainable by the differentiation method and a retinal pigment epithelial cell culture obtained by the differentiation method. In addition, the present invention concerns a retinal pigment epithelium consisting of or comprising a retinal pigment epithelial cell culture obtainable or obtained by the differentiation method. The present invention also relates to a pharmaceutical composition comprising a retinal pigment epithelial cell culture obtained by the differentiation method. The present invention concerns a method of treating a retinal degenerative disease in a subject, comprising administering to a subject a retinal pigment epithelial cell differentiated from the induced pluripotent stem cell by the method.
    Type: Application
    Filed: January 27, 2023
    Publication date: June 19, 2025
    Applicants: Agency for Science, Technology and Research, CellResearch Corporation Pte. Ltd, Singapore Health Services Pte Ltd
    Inventors: Xinyi SU, Regha KAKKAD, Mayuri BHARGAVA, Binxia YANG, Walter HUNZIKER, Zengping LIU, Haofei WANG, Bhav Harshad PARIKH, Qingfeng CHEN, Fritz Shien Choong LAI, Chou CHAI, Kah Leong LIM, Toan Thang PHAN
  • GALNAC-MONOMERS AND GALNAC-NUCLEIC ACID CONJUGATES
    Publication number: 20240327842
    Abstract: GalNAc monomers and GalNAc-oligonucleotide conjugates made using said GalNAc monomers, for example, GalNAc-bearing nucleic acids, e.g. sa-RNAs and siRNAs that may be useful in regulating expression of a target gene.
    Type: Application
    Filed: August 8, 2022
    Publication date: October 3, 2024
    Applicant: LERNA BIOPHARMA PTE. LTD.
    Inventors: Xi LIN, Bing Yuan HAN, Pin Koon EE, Binxia YANG, Joo Leng LOW